Acebutolol
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Acebutolol: From Beta-Blocker Therapy to Malignant Hypertensive Renal Disease
One-Sentence Summary
Acebutolol is an oral beta-blocker (a cardioselective beta-1 blocker with mild intrinsic sympathomimetic activity). The labelled indication text is not included in the source record. The TxGNN model predicts it may be effective for malignant hypertensive renal disease. This prediction has 0 clinical trials and 0 publications directly supporting it, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Malignant hypertensive renal disease |
| TxGNN Prediction Score | 99.10% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 10 (all listed licenses are generic ANDAs) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the record. Based on known drug-class information, acebutolol is a cardioselective beta-1 blocker. Beta-1 blockade reduces renin release, which lowers blood pressure. Hypertension-driven kidney injury is plausibly relevant to that effect.
Malignant hypertensive renal disease is a severe form of hypertension affecting the kidney. It is a subtype of a use already established for the drug class, not a new mechanism. The link is inferred from class pharmacology, not from data in the record.
There is also a practical concern. Malignant hypertension is a hypertensive emergency and is usually managed with parenteral agents. An oral capsule beta-blocker is not an obvious fit. Route compatibility and similarity to the original indication have not yet been assessed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for this indication.
For context, the second-ranked prediction, malignant renovascular hypertension (same score, 99.10%), has one indirect record. PMID 768911 is a 1975 open clinical study in La Nouvelle presse medicale. In it, 50 hypertensive patients received acebutolol alone or with other agents for one year. Treatment was rated good or moderate in 74% of patients and failed in 26%. The abstract also mentions renovascular hypertension, but the record does not show that it addresses the malignant subtype.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA074007 | Acebutolol Hydrochloride (Golden State Medical Supply, Inc.) | Capsule | Not provided in source data |
| ANDA074007 | Acebutolol Hydrochloride (ANI Pharmaceuticals, Inc.) | Capsule | Not provided in source data |
| ANDA075047 | Acebutolol Hydrochloride (AvKARE) | Capsule | Not provided in source data |
| ANDA075047 | Acebutolol Hydrochloride (AvPAK) | Capsule | Not provided in source data |
| ANDA075047 | Acebutolol Hydrochloride (Amneal Pharmaceuticals of New York LLC) | Capsule | Not provided in source data |
Only the oral route (capsule) is available.
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found in the source data.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has only a high model score behind it, with no direct clinical trials or publications. Malignant hypertension is normally treated with parenteral agents, so an oral beta-blocker is a questionable fit. The lack of package insert safety data also blocks progression past the first screening stage.
To proceed, the following is needed:
- Package insert warnings and contraindications (this blocks safety screening)
- Detailed mechanism of action data (MOA)
- Direct clinical evidence for acebutolol in malignant hypertension or hypertensive kidney injury
- A route-compatibility assessment (oral capsule versus the emergency setting)
- A review of how the prediction relates to the drug’s labelled indications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.